Effects of glycoprotein IIb/IIIa blockers [1]

Heart

Volumn 93, Issue 10, 2007, Pages 1293-

  Kalyanasundaram, Arun ^a,c   Berger, Peter ^a   Kastrati, Adnan ^b  

^a GEISINGER MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c 21 60 Department of Cardiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; HEART INFARCTION; HUMAN; LETTER; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE;

EID: 34848921488     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Hernández AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 2007;93:450-5.
2. Braunwald E, Antman EM, Beasley JW, et al. and American College of Cardiology. American Heart Association, Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-900.
3. Bromberg-Marin G, Marin-Neto JA, Parsons LS, et al. National Registry of Myocardial Infarction-4. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Am J Cardiol 2006;98:1125-31.
4. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5.
5. Ndrepepa G, Kastrati A, Mehilli J, et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary intervention. Circulation 2006;114:2040-6.